Home Watchlists Portfolios Indices Forex Futures Market Scan Chart Settings

Bain's Orly Mishan joins Pfizer's neuro spinout Cerevel; Oncolytic virus biotech taps SillaJen exec Helena Chaye as CEO

  • Source: Endpoints News - - Read: 0



    → Bain Cap­i­tal is de­ploy­ing one of its top in­vestors to Cerev­el Ther­a­peu­tics, steer­ing a $350 mil­lion-plus neu­ro play carved out of Pfiz­er. Or­ly Mis­han — a co-founder and prin­ci­pal of Bain’s life sci­ences unit — was in­volved in the part­ner­ship that birthed the biotech spin­out in the first place. As Cerev­el’s first chief busi­ness of­fi­cer, she is tasked with cor­po­rate de­vel­op­ment, pro­gram man­age­ment as well as tech­ni­cal op­er­a­tions.

    Cerev­el launched last Oc­to­ber af­ter Adam Kop­pel spear­head­ed a deal to spin the neu­ro­sciences pro­grams Pfiz­er had aban­doned (along­side 300 staffers) out to a new, well fund­ed com­pa­ny. Since then it’s been build­ing out its own team, fill­ing the lead­er­ship ranks with alum­ni of Sang­amo, Ot­su­ka and Mer­ ...



    Read Full News: https://endpts.com/bains-orly-mishan-joins-pfizers-neuro-spinout-cerevel-oncolytic-virus-biotech-taps-sillajen-exec-helena-chaye-as-ceo/

Log in to reply